Related Experiment Video

Updated: Oct 9, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Role of TGF-beta in immune-evasion of cancer

C Beck1, H Schreiber, D Rowley

  • 1Immunology Division, Department of Pathology, University of Chicago, Chicago, Illinois 60637, USA. c.beck@med2.uni-kiel.de

Microscopy Research and Technique
|February 15, 2001
PubMed

Insights

Transforming growth factor beta (TGF-beta), bound by immunoglobulin G (IgG-TGF-beta) and secreted by B cells, may suppress anti-tumor immunity. This mechanism, mediated by myeloid cells, offers targets for enhancing cancer immunity.

Area of Science:

  • Immunology
  • Cancer Biology
  • Molecular Biology

Background:

  • Tumor-immunology faces challenges with malignant tumor growth despite immune recognition.
  • Transforming growth factor beta (TGF-beta) is a cytokine with diverse roles, including immunoregulation.
  • Cytolytic T cells (CTL) are crucial for immune elimination of cancers.

Purpose of the Study:

  • To review the potential role of TGF-beta in tumor immune evasion.
  • To propose a novel mechanism of CTL suppression mediated by immunoglobulin-bound TGF-beta (IgG-TGF-beta).

Main Methods:

  • Review of existing literature on TGF-beta and tumor immunology.
  • Proposal of a hypothetical mechanism involving IgG-TGF-beta and myeloid "Veto" cells.
  • Analysis of supporting evidence from B cell-deficient mouse models.

Main Results:

  • TGF-beta is implicated in immune regulation and potentially tumor immune evasion.
  • A mechanism is proposed where IgG-TGF-beta, secreted by B cells and myeloid cells, suppresses CTL responses.
  • B cell activity appears to influence tumor rejection, as suggested by studies in deficient mice.

Conclusions:

  • IgG-TGF-beta secreted by B cells and myeloid cells may be a key factor in tumor immune evasion by suppressing CTLs.
  • Interfering with the IgG-TGF-beta network presents a potential strategy for enhancing anti-cancer immunity.

More Related Videos

Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...